To the Editor,
I read with interest your article entitled “Panel Grapples With the Role of Biosimilars in Oncology” that reported on The Atlantic’s panel discussion of June 1, 2018, on the role that biosimilars will play in cancer care.
Although you accurately reported comments from Mr. Andrew Spiegel of the Global Colon Cancer Association, I am concerned that some of his statements will perpetuate misconceptions about biosimilars. Mr. Spiegel stated that the European experience with biosimilars was inadequate because the European health authorities did not require pharmacovigilance reporting with the same rigor as required in the United States, suggesting that we do not have convincing data supporting the post-approval safety profile of biosimilars marketed in Europe.
These assertions are far from the truth.
There are many European Union member countries with sizable populations that have advanced pharmacovigilance systems that are as excellent as any pharmacovigilance system in the world.
Ever since the approval of Omnitrope (somatropin) in Europe in 2006 as the world’s first biosimilar, EU health authorities have subjected all EU-approved biosimilars to the very same pharmacovigilance reporting standards, post-approval studies and periodic re-analyses of benefit-risk profile as any other newly approved biological drug.
Based on the extensive and well-executed pharmacovigilance reporting associated with 700 million patient-days of exposure to biosimilars in the European Union,1 the European Medicines Agency (EMA) concluded in 2017 that “The EU monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilar medicines and their reference medicines.”2
Healthcare professionals and the public in the United States can be reassured: well-designed biosimilars approved to the standards of the FDA and EMA are as safe and effective for their intended use as their respective reference medicines.
References
1. Biosimilar Medicines Group, a Medicines for Europe sector group. Comment on the Food and Drug Administration Notice: Oncologic Drugs Advisory Committee meeting (Docket FDA-2017-N-2732). Regulations.gov. https://www.regulations.gov/document?D=FDA-2017-N-2732-0006. Published June 26, 2017. Accessed June 7, 2018.
2. European Medicines Agency. Biosimilars in the EU: Information guide for healthcare professionals. European Medicines Agency website. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Published April 27, 2017. Accessed June 4, 2018.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.